EGFR

Oncology

ESMO26: Taiho Oncology on improving the lives of patients wi...

Dr Harold Keer, chief medical officer at Taiho Oncology, discusses the Phase 2 REZILIENT2 trial data presented at ESMO26 and the NSCLC setting.

News

ESMO26: BMS dual-acting ADC beats chemo in breast cancer

BMS and SystImmune's EGFRxHER3 bispecific ADC iza-bren has scored in another phase 3 trial, boosting its credentials as a future blockbuster.

News

Hutchmed rises on $1.3bn KRAS licensing deal with GSK

GSK has paid Hutchmed $110m upfront for rights to a preclinical KRAS and EGFR-directed drug with potential in colorectal, pancreatic, and lung cancer.

Oncology

EGFR-mutant lung cancer: Cracking the drug resistance code

Targeted therapies have transformed the treatment landscape for non-small cell lung cancer (NSCLC) over the past decade.

News

Dizal breaks new ground for EGFR drugs in lung cancer

Dizal's Zegfrovy has taken the oral EGFR inhibitor class into new territory, with a phase 3 win as a frontline treatment for a form of lung cancer.

News

Survival data back Tagrisso's role in first-line lung cancer

Can survival data from the FLAURA2 trial of Tagrisso help AstraZeneca fend off a challenge from J&J's fast-growing rival in EGFR-mutated lung cancer?

ESMO26: Taiho Oncology on improving the lives of patients wi...

ESMO26: BMS dual-acting ADC beats chemo in breast cancer

Hutchmed rises on $1.3bn KRAS licensing deal with GSK

EGFR-mutant lung cancer: Cracking the drug resistance code

Dizal breaks new ground for EGFR drugs in lung cancer

Survival data back Tagrisso's role in first-line lung cancer

Flagship joins three biotechs together to form Etcelera

Discover a new era of healthcare panel engagement: Grounded ...

EGFR

Editor's Picks